Why the study?
Pulmonary artery denervation can reduce sympathetic nervous system activity and pulmonary artery pressure in pulmonary hypertension, prompting a systematic meta-analysis to evaluate its overall effectiveness.
Does pulmonary artery denervation improve hemodynamics and functional capacity in patients with pulmonary hypertension?
Does pulmonary artery denervation improve hemodynamics and functional capacity in patients with pulmonary hypertension?
Pulmonary artery denervation significantly improves hemodynamic parameters and functional capacity in patients with pulmonary hypertension, supporting its potential as a novel therapeutic strategy.
PADN may offer a novel PH option; extends early trial data but leaves open confirmation in large RCTs.
INTRODUCTION: Pulmonary artery denervation (PADN) can reduce the sympathetic nervous system (SNS) activity, reduce pulmonary artery pressure (PAP), and improve the quality of life in patients with pulmonary hypertension (PH). We conducted a systematic meta-analysis of the effectiveness of PADN in the treatment of PH patients. METHODS: This is a comprehensive literature search including all public clinical trials investigating the effects of PADN on PH. Outcomes were mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac output (CO), right ventricular (RV) Tei index, 6-minute walk distance (6MWD), and New York Heart Association (NYHA) cardiac function grading. RESULTS: A total of eight clinical studies with 213 PH patients who underwent PADN were included. Meta-analysis showed that after PADN, mPAP (mean difference [] -12.51, 95% confidence interval [CI] -17.74 to -7.27, P<0.00001) (mmHg) and PVR ( -5.17, 95% CI -7.70 to -2.65, P<0.0001) (Wood unit) decreased significantly, CO ( 0.59, 95% CI 0.32 to 0.86, P<0.0001) (L/min) and 6MWD ( 107.75, 95% CI 65.64 to 149.86, P<0.00001) (meter) increased significantly, and RV Tei index ( -0.05, 95% CI -0.28 to 0.17, P=0.63) did not change significantly. Also after PADN, the proportion of NYHA cardiac function grading (risk ratio 0.23, 95% CI 0.14 to 0.37, P<0.00001) III and IV decreased significantly. CONCLUSION: This meta-analysis supports PADN as a potential new treatment for PH. Further high-quality randomized controlled studies are needed.
No takes yet. Share an insight, caveat, or question.
Zuo et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: